• Home
  • » 
  • Reports
  • » 
  • Parkinson's Disease Market: Pipeline Review, Developer Landscape and Competitive Insights | Industry Analysis | Market Size |

Parkinson's

Parkinson's Disease Market: Pipeline Review, Developer Landscape and Competitive Insights [Upcoming Report]

  • Lowest Price Guaranteed From USD 2,349

  • Published
    May 2018

  • Pages
    204

  • View Count
    7222

  • Buy Now

Example Insights

   

 

Report Description

Parkinson’s disease is a chronic disorder that gradually leads to progressive deterioration of motor functions due to loss of dopamine-producing brain cells. It is presently the second most common neurodegenerative disease (after Alzheimer’s disease) and is characterized by symptoms such as shaking, rigidity, difficulty in walking / movement, and several other cognitive and behavioral problems. Parkinson’s disease is known to affect 1-2 per 1,000 individuals and has been shown to impact approximately 1% of the population aged above 60 years. It is also worth highlighting that, every year, nearly 60,000 Americans are diagnosed with Parkinson’s. The disease has been estimated to incur combined direct and indirect costs of close to USD 25 billion in the US annually. With increasing disease prevalence and the corresponding growth in socioeconomic burden, the field faces a pressing need for accurate diagnostic (predictive) tests, and efficient treatment options for slowing the progression of the disease. Despite the availability of several types of dopamine agonists, there still are a myriad of motor and non-motor symptoms that currently available therapies are unable to treat.

The unavailability of neuroprotective therapies remains one of the prime unmet needs in this domain. The disease is highly complex and is known to render any single therapeutic approach inadequate to deal with its multifaceted etiopathogenesis. Currently, several stakeholders in the pharmaceutical industry are engaged in efforts to advance the development of various types of disease modifying pharmacological interventions, therapies to offer symptomatic relief and drugs to try to cure the disease as well. In fact, there are multiple initiatives established by start-ups that are being backed by venture capital funding to expedite the development of potential therapeutic options for better disease management.

 

Scope of the Report

The “Parkinson’s Disease Market: Pipeline Review, Developer Landscape and Competitive Insights"  report provides an extensive study on the marketed, clinical and preclinical molecules being investigated for the treatment of Parkinson’s disease. Figure 1 summarizes the scope of the report and the specific modules that have been covered in extensive detail.

Figure 1 Parkinson’s Disease: Scope and Competitive Insights

Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of drugs being developed for the treatment of Parkinson’s disease, providing information on drug developer(s), phase of development (clinical, preclinical / discovery stage) of product candidates, type of molecule (small molecule, biologic or gene / cell therapy), treatment type (disease modifying agent, drugs offering symptomatic relief or drugs for curing the disease), mechanism of action, and route of administration.
  • An in-depth analysis of the product pipeline and developer companies, featuring four schematic representations; these include [A] a heptagon representation highlighting the distribution of the marketed and development stage molecules based on their mechanisms of action, [B] a 2X2 grid analysis, representing the distribution of drug candidates across various molecule types and stages of development, [C] a funnel analysis highlighting the distribution of molecules (segregated by stage of development) based on route of administration and treatment type, and [D] a logo landscape of the various industry players involved in the development of drugs, distributed on the basis of location of headquarters and company size (small-sized, mid-sized and large).
  • An analysis highlighting the key unmet needs across Parkinson’s disease, featuring insights generated from real-time data on unmet needs as identified from social media posts, recent publications, patient blogs and the views of key opinion leaders expressed on online platforms.
  • Comprehensive profiles of drugs in phase III of clinical development, with information on the developer, specific target patient population, mechanism of action, clinical trials, current status of development, and recent developments (if available).
  • An insightful competitive analysis, highlighting the key players in the domain on the basis of the strength of their development portfolio. For all companies that emerged as important players in this field, we have presented a five-dimensional spider web analysis,  taking into account the company’s size, activity on Google Trends, stage of development of lead molecule, strength of the Parkinson’s disease pipeline and the (present) number of clinical trials being conducted by the player.
  • A detailed analysis of the mergers and acquisitions that have taken place in this space, highlighting the trend in the number of companies acquired in the last few years, along with the geographical distribution of this activity. The analysis features an ownership change matrix and presents a financial evaluation of these deals (revenues and respective deal multiples) as well.
  • A detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field, and a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers involved in the development of molecules in this domain.
  • An analysis of the investments made at various stages of development in companies that are focused in this area, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings.
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in development of anti-Parkinson’s therapeutics.

The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered from both secondary and primary sources. The opinions and insights presented in this study were influenced by inputs (through a comprehensive survey) of several key players in this domain. All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the Parkinson’s disease market in the long term.

Chapter 3  provides an introduction to Parkinson’s disease. It provides a detailed discussion on the history, symptoms and stages of Parkinson’s disease, factors influencing disease progression and the various treatment regimens that are available in the market. The section also highlights the epidemiology of the disease and its economic burden across various regions.

Chapter 4  includes information on close to 190 molecules that are currently approved / under development for therapeutic use. It features a comprehensive analysis of pipeline molecules, highlighting the phase of development (clinical, preclinical / discovery stage) of product candidates, type of molecule (small molecule, biologic or gene / cell therapy), treatment type (disease modifying agent, drugs offering symptomatic relief or drugs for curing the disease), mechanism of action, and route of administration. In addition, it presents certain key insights derived from the study, which include a heptagon representation highlighting the distribution of the marketed and pipeline molecules based on different mechanisms of action. The chapter includes a comprehensive 2X2 grid analysis, representing the distribution of the drug candidates across various molecule types and stages of development, and a funnel analysis highlighting the distribution of molecules on the basis of stage of development, route of administration and treatment type. Additionally, the chapter features a logo landscape of developers engaged in this domain, distributed on the basis of location of headquarters and size of the company.

Chapter 5  highlights the key unmet needs associated with the management and treatment of Parkinson’s disease. The chapter provides detailed analysis of unmet needs that were identified from views expressed by patients / experts across different platforms, such as social media posts, recent publications and patient blogs, and the inputs of key opinion leaders at conferences / symposiums. The chapter presents an insightful sentiment analysis and word cloud analysis, summarizing the opinions expressed across the public portals.

Chapter 6  contains detailed profiles of drugs that are in phase III of clinical development. Each profile features an overview of the developer, and provides information on the status of development, target population, mechanism of action, results of clinical trials ( if available ) and recent developments ( if available ).

Chapter 7  features an insightful competitive analysis, highlighting the most active players in this domain on the basis of their activity (in terms of developing therapeutics for Parkinson’s disease). For each of the shortlisted companies, we have presented a spider web analysis highlighting the company’s size, activity on Google, stage of development of lead molecule, strength of the Parkinson’s disease pipeline and the (present) number of clinical trials being conducted by the player.

Chapter 8  presents a detailed analysis of the mergers and acquisitions that have taken place in this industry. The chapter provides information on the acquiring and acquired companies (headquarters and the ownership (public / private)), along with the year of acquisition, acquiring amount ( if available ), and the financial status of the acquired company at the time of acquisition. It features a detailed ownership change matrix depicting the distribution of mergers and acquisitions across private firms, public firms and sole proprietorships. It also includes an evaluation of the financials of these deals (revenues of the acquired firms at the time of acquisition and their respective deal multiples).

Chapter 9  provides an analysis of KOLs in the field of Parkinson’s disease. It features a comprehensive list of principal investigators of different clinical trials, along with information related to the affiliated research institutes. The chapter features a schematic representation on a world map, highlighting the geographical locations of eminent scientists / researchers who are engaged in clinical research in this domain. It also features a comparative analysis, highlighting those KOLs who have relatively more experience in this domain.

Chapter 10  presents details on various investments received by companies that are engaged in this domain. It also includes an analysis of the funding instances that have taken place amongst the start-ups in the period between 2010 and March 2018, highlighting the growing interest of the venture capital community and other strategic investors in this market.

Chapter 11  presents the insights generated from a detailed survey, wherein we invited multiple stakeholders involved in development of therapeutics for Parkinson’s disease. The participants, who were primarily Directors / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 12  is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 13  is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. An Overview of Parkinson’s Disease
3.1.1. History and Causes
3.1.2. Symptoms
3.1.3. Epidemiology
3.1.4. Economic Burden
 
3.2. Parkinson’s Disease Management
3.2.1. Pharmacological Management of Parkinson’s Disease
3.2.2. Non-Pharmacological Management of Parkinson’s Disease
3.2.3. Management of Parkinson’s Disease Using Dietary Supplements
3.2.4. Convenient Remedies to Manage Parkinson’s Disease
 
4. PIPELINE REVIEW: MARKETED AND DEVELOPMENT DRUGS
4.1. Chapter Overview
4.2. Parkinson’s Disease: Marketed and Development Pipeline
4.3. Parkinson’s Disease: Pipeline Analysis
4.3.1. Distribution by Phase of Development
4.3.2. Distribution by Type of Treatment
4.3.3. Distribution by Type of Molecule
4.3.4. Distribution by Mechanism of Action
4.3.5. Distribution by Route of Administration
4.3.6. Distribution by Leading Players
4.3.7. Funnel Analysis: Distribution by Phase of Development, Treatment Type and Route of Administration
4.3.8. Heptagon Representation: Distribution by Mechanism of Action and Phase of Development
4.3.9. Grid Analysis: Distribution by Type of Molecule and Phase of Development
4.3.10. Developer Logo Landscape: Distribution by Company Size and Location
 
5. PARKINSON’S DISEASE: UNMET NEED ANALYSIS
5.1. Chapter Overview
5.2. Unmet Need Analysis for Parkinson’s Disease
5.2.1. Analysis Overview
 
5.2.2. Blogposts by Patients
5.2.2.1. Methodology
5.2.2.2. Affiliated Insights
 
5.2.3. Published Literature
5.2.3.1. Methodology
5.2.3.2. Affiliated Insights
 
5.2.4. Social Media Platforms
5.2.4.1. Methodology
5.2.4.2. Affiliated Insights
 
5.2.5. Expert Opinions
5.2.5.1. Rajesh Pahwa, University of Kansas Medical Center, US
5.2.5.2. V Natarajan, Professor of Neurology, Institute of Neurology, Madras Medical College, India
5.2.5.3. Richard Wade-Martins, Oxford Parkinson’s Disease Center (OPDC) Principal Investigator; Michele Hu, OPDC Clinical Lead; Mark Kelly, OPDC; James Cantley, Department of Physiology, Anatomy and Genetics, University of Oxford, UK
5.2.5.4. K Ray Chaudhuri, Professor of Neurology/Movement Disorders at King's College Hospital, UK
5.2.5.5. Daniel M Cocos, Professor of Physical Therapy & Human Movement Sciences, Feinberg School of Medicine, North-eastern University, US
5.2.5.6. Rachel Dolhun, MD, Neurologist and Movement Disorder Specialist, US
5.2.6. Key Unmet Needs in Parkinson’s Disease
 
6. DRUG PROFILES: PHASE III MOLECULES
6.1. Chapter Overview
6.2. Drug Profile: Accordion Pill - Carbidopa / Levodopa (Intec Pharma)
6.3. Drug Profile: APL-130277 / Apomorphine Hydrochloride (Sunovion)
6.4. Drug Profile: Apomorphine Hydrochloride (Britannia Pharmaceuticals)
6.5. Drug Profile: Apomorphine Infusion (US WorldMeds)
6.6. Drug Profile: Istradefylline / KW-6002 (Kyowa Hakko Kirin)
6.7. Drug Profile: ND0612 (NeuroDerm)
6.8. Drug Profile: P2B001 (Pharma Two B)
 
7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Methodology
7.2.1. Assumptions and Key Parameters
 
7.3. Affiliated Insights
7.3.1. Spider Web Competitive Analysis: AbbVie
7.3.2. Spider Web Competitive Analysis: Acorda Therapeutics
7.3.3. Spider Web Competitive Analysis: Addex Therapeutics
7.3.4. Spider Web Competitive Analysis: Axovant Sciences
7.3.5 Spider Web Competitive Analysis: Integrative Research Laboratories
7.3.6. Spider Web Competitive Analysis: Kyowa Hakko Kirin
7.3.7. Spider Web Competitive Analysis: NeuroDerm
7.3.8. Spider Web Competitive Analysis: Sunovion
7.3.9. Spider Web Competitive Analysis: UCB
 
8. MERGERS AND ACQUISITIONS
8.1. Chapter Overview
8.2. Parkinson’s Disease: Mergers and Acquisitions
8.2.1. Mergers and Acquisitions: Analysis by Year
8.2.2. Mergers and Acquisitions: Geographical Activity
8.2.3. Mergers and Acquisitions: Ownership Change Matrix
8.3. Key Acquisitions: Deal Multiples
 
9. KOL ANALYSIS
9.1. Chapter Overview
9.2. Methodology
 
9.3. Current Researcher Landscape
9.3.1. Prominent Key Opinion Leaders
9.4. Geographical Location of Key Opinion Leaders
 
9.5. Most Active Key Opinion Leaders
9.5.1. KOL Profile: Robert Hauser, College of Medicine Neurology
9.5.2. KOL Profile: Mika Scheinin, University of Turku
 
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. Parkinson’s Disease Therapy Developers: Funding and Investment Analysis
10.3.1. Analysis by Cumulative Number of Funding Instances
10.3.2. Analysis by Cumulative Amount Invested
10.3.3 Analysis by Type of Funding
10.3.4 Analysis by Most Active Players
10.3.5. Analysis by Most Active Investors
 
11. SURVEY ANALYSIS
11.1. Chapter Overview
11.2. Parkinson’s Disease Therapeutics: Phase of Development
11.3. Parkinson’s Disease Therapeutics: Drug Classes
11.4. Parkinson’s Disease Therapeutics: Partnerships
11.5. Parkinson’s Disease Therapeutics: Current Market Opportunity
11.6. Parkinson’s Disease Therapeutics: Future Market Opportunity
 
12. APPENDIX 1: TABULATED DATA
 
13 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

List of Figures

Figure 3.1 Parkinson’s Disease: Historical Timeline
Figure 3.2 Celebrities Diagnosed with Parkinson’s Disease
Figure 3.3 Parkinson’s Disease: Causal Environmental Factors
Figure 3.4 Parkinson’s Disease: Disease Stages
Figure 3.5 Parkinson’s Disease: Motor Symptoms
Figure 3.6 Parkinson’s Disease: Secondary Symptoms
Figure 3.7 Parkinson’s Disease: Gender-wise Incidence Rates
Figure 3.8 Parkinson’s Disease: Geography-wise Incidence Rates
Figure 3.9 Parkinson’s Disease: Direct and Indirect Costs
Figure 3.10 Parkinson’s Disease Management: Pharmacological Treatment Options
Figure 3.11 Parkinson’s Disease Management: Non-Pharmacological Treatment Options
Figure 3.12 Parkinson’s Disease Management: Surgical Methods
Figure 3.13 Parkinson’s Disease Management: Dietary Supplements
Figure 4.1 Pipeline Analysis: Distribution by Phase of Development
Figure 4.2 Pipeline Analysis: Distribution by Type of Treatment
Figure 4.3 Pipeline Analysis: Distribution by Type of Molecule
Figure 4.4 Pipeline Analysis: Distribution by Mechanism of Action
Figure 4.5 Pipeline Analysis: Distribution by Route of Administration
Figure 4.6 Pipeline Analysis: Leading Players
Figure 4.7 Funnel Analysis: Distribution by Type of Treatment, Route of Administration and Development Stage
Figure 4.8 Heptagon Representation: Distribution by Mechanism of Action and Development Stage
Figure 4.9 Grid Analysis: Distribution by Type of Molecule and Development Stage
Figure 4.10 Developer Logo Landscape: Distribution by Size and Location
Figure 5.1 Unmet Need Analysis: Overview of the Methodology
Figure 5.2 Unmet Need Analysis: Word Cloud of Patient Blogs
Figure 5.3 Unmet Need Analysis: Number of Publications, Year-wise Trend
Figure 5.4 Unmet Need Analysis: Needs Highlighted in Published Literature
Figure 5.5 Social Media Analysis: Overview of the Methodology
Figure 5.6 Social Media Analysis: Sentiment Analysis
Figure 5.7 Social Media Analysis: Word Cloud of the Tweets
Figure 5.8 Social Media Analysis: Trends
Figure 5.9 Social Media Analysis: Most Prolific Authors / Contributors
Figure 5.10 Social Media Analysis: Word Clouds highlighting Unmet Needs 
Figure 5.11 Social Media Analysis: Celebrities Suffering from Parkinson’s Disease (Word Cloud)
Figure 5.12 Summary of Key Unmet Needs in Parkinson’s Disease
Figure 7.1 Company Competitiveness Analysis: Methodology
Figure 7.2 Company Competitiveness Analysis: Dot-Plot Representation
Figure 7.3 Spider Web Competitive Analysis: AbbVie
Figure 7.4 Spider Web Competitive Analysis: Acorda Therapeutics
Figure 7.5 Spider Web Competitive Analysis: Addex Therapeutics
Figure 7.6 Spider Web Competitive Analysis: Axovant Sciences
Figure 7.7 Spider Web Competitive Analysis: Integrative Research Laboratories
Figure 7.8 Spider Web Competitive Analysis: Kyowa Hakko Kirin
Figure 7.9 Spider Web Competitive Analysis: NeuroDerm
Figure 7.10 Spider Web Competitive Analysis: Sunovion
Figure 7.11 Spider Web Competitive Analysis: UCB
Figure 8.1 Parkinson’s Disease Mergers and Acquisitions: Year-Wise Trend
Figure 8.2 Parkinson’s Disease Mergers and Acquisitions: Geographical Activity
Figure 8.3 Parkinson’s Disease Mergers and Acquisitions: Distribution by International and Local Deals
Figure 8.4 Parkinson’s Disease Mergers and Acquisitions: Ownership Change Matrix
Figure 9.1 KOL Analysis: Overview of Methodology
Figure 9.2 KOL Analysis: Dot-Plot of Principal Investigators
Figure 9.3 KOL Analysis: Geographical Location of Principal Investigators
Figure 9.4 KOL Analysis: Most Active Key Opinion Leaders
Figure 10.1 Parkinson’s Disease Therapy Developers: Cumulative Number of Funding Instances, 2010-2018
Figure 10.2 Parkinson’s Disease Therapy Developers: Distribution of Amount Invested by Year, 2010-2018 (USD Million)
Figure 10.3 Parkinson’s Disease Therapy Developers: Distribution by Type of Funding, 2010-2018
Figure 10.4 Parkinson’s Disease Therapy Developers: Distribution of Total Amount Invested by Type of Funding, 2010-2018 (USD Million)
Figure 10.5 Parkinson’s Disease Therapy Developers: Most Active Players by Number of Funding Instances
Figure 10.6 Parkinson’s Disease Therapy Developers: Most Active Investors by Number of Funding Instances
Figure 11.1 Survey Analysis: Distribution by Phase of Development
Figure 11.2 Survey Analysis: Distribution by Drug Classes
Figure 11.3 Survey Analysis: Distribution by Number of Partnerships
Figure 11.4 Survey Analysis: Distribution by Current Market Opportunity
Figure 11.5 Survey Analysis: Distribution by Future Opportunity

List of Tables

Table 3.1  Parkinson’s Disease Management: Combination Therapies
Table 4.1  Parkinson’s Disease: Marketed and Development Pipeline 
Table 6.1  Parkinson’s Disease: Phase III Molecules
Table 6.2  Drug Profile: Accordion Pill – Carbidopa / Levodopa (Intec Pharma)
Table 6.3  Drug Profile: Apomorphine Hydrochloride/ APL-130277 (Sunovion)
Table 6.4  Drug Profile: Apomorphine Hydrochloride (Britannia Pharmaceuticals)
Table 6.5  Drug Profile: Apomorphine Infusion (US WorldMeds)
Table 6.6  Drug Profile: Istradefylline / KW-6002 (Kyowa Hakko Kirin)
Table 6.7  Drug Profile: ND0612 (NeuroDerm)
Table 6.8  Drug Profile: P2B001 (Pharma Two B)
Table 7.1  Parkinson’s Disease Therapy Developer Competitive Analysis: Shortlisted Companies
Table 7.2  Parkinson’s Disease Therapy Developer Competitive Analysis: Spider Web Parameters
Table 8.1  Parkinson’s Disease: Mergers and Acquisitions
Table 8.2  Parkinson’s Disease Acquisitions: Deal Multiples
Table 9.1  KOL Analysis: List of Principal Investigators 
Table 9.2  KOL Analysis: Scoring System
Table 9.3  KOL Analysis: List of Universities and Hospitals
Table 9.4  KOL Profile: Robert Hauser, Clinical Trials
Table 9.5  KOL Profile: Robert Hauser, Published Literature
Table 9.6  KOL Profile: Mika Scheinin, Clinical Trials
Table 9.7  KOL Profile: Mika Scheinin, Published Literature
Table 10.1 Parkinson’s Disease Therapy Developers: Funding and Investment Analysis 
Table 10.2 Parkinson’s Disease: Summary of Investments
Table 11.1 Survey Respondents: Overview
Table 11.2 Survey Response: Parkinson’s Disease Therapeutics Phase of Development
Table 11.3 Survey Responses: Parkinson’s Disease Therapeutics Drug Classes
Table 11.4 Survey Responses: Parkinson’s Disease Therapeutics Partnerships
Table 11.5 Survey Responses: Parkinson’s Disease Therapeutics Current Market Opportunity
Table 11.6 Survey Responses: Parkinson’s Disease Therapeutics Future Opportunity
Table 12.1 Parkinson’s Disease: Gender-wise Incidence Rates
Table 12.2 Parkinson’s Disease: Direct and Indirect Costs
Table 12.3 Pipeline Analysis: Distribution by Phase of Development
Table 12.4 Pipeline Analysis: Distribution by Type of Treatment
Table 12.5 Pipeline Analysis: Distribution by Type of Molecule
Table 12.6 Pipeline Analysis: Distribution by Mechanism of Action
Table 12.7 Pipeline Analysis: Distribution by Route of Administration
Table 12.8 Pipeline Analysis: Leading Players
Table 12.9 Unmet Needs in Parkinson’s Disease: Number of Publications, Year-wise Trend
Table 12.10 Unmet Needs in Parkinson’s Disease: Unmet Needs Highlighted in Published Literature
Table 12.11 Unmet Needs in Parkinson’s Disease: Social Media Platforms, Sentiment Analysis
Table 12.12 Unmet Needs in Parkinson’s Disease, Social Media Analysis: Most Prolific Authors
Table 12.13 Company Competitiveness Analysis: Dot-Plot Representation
Table 12.14 Spider-Web Analysis: Shortlisted Companies
Table 12.15 Mergers and Acquisitions: Year-Wise Trend
Table 12.16 Mergers and Acquisitions: Geographical Activity
Table 12.17 Mergers and Acquisitions: Distribution by International and Local Acquisitions
Table 12.18 Mergers and Acquisitions: Ownership Change Matrix
Table 12.19 KOL Analysis: Dot-Plot of Principal Investigators
Table 12.20 Parkinson’s Disease Therapeutics Developer: Cumulative Number of Funding Instances, 2010-2018
Table 12.21 Parkinson’s Disease Therapeutics Developer: Distribution of Amount Invested by Year, 2010-2018 (USD Million)
Table 12.22 Parkinson’s Disease Therapeutics Developer: Distribution by Type of Funding, 2010-2018
Table 12.23 Parkinson’s Disease Therapeutics Developer: Distribution of Total Amount Invested by Type of Funding, 2010-2018 (USD Million)
Table 12.24 Parkinson’s Disease Therapeutics Developer: Most Active Players by Number of Funding Instances
Table 12.25 Parkinson’s Disease Therapeutics Developer: Most Active Investors by Number of Funding Instances
Table 12.26 Survey Analysis: Distribution by Phase of Development
Table 12.27 Survey Analysis: Distribution by Drug Classes
Table 12.28 Survey Analysis: Distribution by Number of Partnerships
Table 12.29 Survey Analysis: Distribution by Current Market Opportunity
Table 12.30 Survey Analysis: Distribution by Future Opportunity

Listed Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 3M New Ventures
  2. 4P Therapeutics
  3. 5AM Ventures
  4. Abbott
  5. AbbVie
  6. AC Immune
  7. ACADIA Pharmaceuticals
  8. Accera
  9. Acelot 
  10. Acino
  11. Acorda Therapeutics
  12. Addenbrooke's Hospital
  13. Addex Therapeutics
  14. Aeolus Pharmaceuticals
  15. Aestas Pharma
  16. AFFiRiS
  17. Alliance of Angels
  18. AMAbiotics
  19. Amarantus BioScience
  20. Amgen
  21. aMoon
  22. Anavex Life Sciences
  23. Antoxis 
  24. ApoPharma
  25. Araclon Biotech
  26. ArmaGen
  27. Armistice Capital
  28. Arrien Pharmaceuticals
  29. Asceneuron
  30. AstraZeneca
  31. Atlas Venture
  32. Auckland City Hospital
  33. Avanir Pharmaceuticals
  34. Avant Diagnostics
  35. Axovant Sciences
  36. AZTherapies
  37. Azur Pharma
  38. Babraham Research Campus
  39. Bayer
  40. Ben Franklin Technology Partners
  41. BenevolentAI
  42. Bertin Bioreagent
  43. BIAL
  44. BioAdvance
  45. BioArctic
  46. BioElectron Technology 
  47. Biogen  
  48. BioReference Laboratories
  49. Biotie Therapeutics
  50. BlueRock Therapeutics
  51. Boehringer Ingelheim Venture Fund
  52. Bpifrance
  53. BrainStorm Cell Therapeutics
  54. BrainX
  55. Britannia Pharmaceuticals
  56. Brookside Capital
  57. Bukwang Pharmaceutical
  58. Burkina Faso Caisses Populaires
  59. BVF Partners
  60. Caixa Capital Risc
  61. Callaghan Innovation
  62. Canadian Institutes of Health Research
  63. Cantabio Pharmaceuticals
  64. Capo Therapeutics
  65. Carna Biosciences
  66. Casdin Capital
  67. Cedars-Sinai Medical Center
  68. Celavie Biosciences
  69. Celerion
  70. Cellix Bio
  71. Centurion Private  
  72. Cerevance
  73. Chelsea Therapeutics
  74. Chinese Academy of Sciences
  75. Chipscreen Biosciences
  76. Clera
  77. CleveXel Pharma
  78. Clinical Research Services Turku
  79. Cobra Biologics  
  80. Collaborative Medicinal Development
  81. Collidion
  82. Columbia University Irving Medical Center
  83. Commission for Technology and Innovation
  84. Contera Pharma
  85. Corium 
  86. Cormorant Asset Management
  87. Crossroad FCP
  88. Curemark
  89. Cynapsus Therapeutics
  90. Dart NeuroScience
  91. Dementia Discovery Fund
  92. Denali Therapeutics
  93. DermaXon
  94. Desitin Arzneimittel
  95. Deutsche Parkinson Vereinigung
  96. Discover Growth Fund
  97. Domain Therapeutics
  98. Dominion Capital
  99. Dong-A ST
  100. Duke University Health Center
  101. Eli Lilly
  102. Emory University
  103. Enterin
  104. Fabre-Kramer Pharmaceuticals
  105. Federal University of São Paulo
  106. Forbion Capital Partners
  107. Friedrich-Baur-Institute 
  108. Fulcrum Therapeutics
  109. Gabriel Capital Management
  110. Gene Therapy Research Institution
  111. Generali Financial Holdings
  112. Genervon Biopharmaceuticals
  113. Genomia
  114. GlaxoSmithKline
  115. GNT Pharma
  116. Grampian Biopartners
  117. Hammersmith Medicines Research
  118. Hatteras Venture Partners
  119. HealthEquity
  120. Henri Mondor Hospital
  121. Henry Ford West Bloomfield Hospital 
  122. Herantis Pharma
  123. Hercules Capital
  124. Herculis Partners
  125. Highland Capital Management
  126. Histostem
  127. Hôpital Pitié-Salpêtrière  
  128. Horizon Technology Finance
  129. Hospital Angeles Pedregal
  130. Hospital Sant Pau  
  131. Hypnion
  132. Idec Pharmaceuticals
  133. IIB Sant Pau
  134. Immungenetics
  135. IMPAX Laboratories
  136. Impel NeuroPharma
  137. Imperial Innovations 
  138. Index Ventures
  139. Inhibikase Therapeutics
  140. Innovate UK
  141. Innovative California Biosciences International
  142. Intec Pharma
  143. Integrative Research Laboratories
  144. International Infusion
  145. International Stem Cell Corporation
  146. Intra-Cellular Therapies
  147. Invercaria
  148. Io Therapeutics
  149. IRCCS Ospedale San Raffaele
  150.  Israel Biotech Fund
  151. Israel Innovation Authority
  152. Jazz Pharmaceuticals
  153. JEIL Pharmaceutical
  154. Jichi Medical University
  155. JK&B Capital
  156. Johns Hopkins University 
  157. Johnson & Johnson
  158. Junaxo
  159. Kainos Medicine
  160. Kapital Assets
  161. Khondrion
  162. KISSEI Pharmaceutical
  163. Korea Drug Development Fund
  164. K-PAX Pharmaceuticals
  165. Kyowa Hakko Kirin
  166. Lightstone Ventures
  167. Lincoln Park Capital Fund
  168. Living Cell Technologies
  169. Loma Linda University Health
  170. Longevity Biotech
  171. LTS Lohmann Therapie-Systeme 
  172. Luc Therapeutics
  173. Lundbeck
  174. Luye Pharma Group
  175. Lysosomal Therapeutics
  176. MedGenesis Therapeutix
  177. Medical University of Innsbruck
  178. Med-Life Discoveries
  179. Melbourne Health
  180. Melior Pharmaceuticals
  181. Merck Ventures
  182. Mérieux Développement
  183. Mertz Holdings
  184. Metabolic Solutions Development 
  185. MIG Verwaltungs
  186. Minerva Neurosciences
  187. Ministry of Health (Brazil)
  188. Mission Therapeutics
  189. Mitochon Pharmaceuticals
  190. Mitsubishi Tanabe Pharma
  191. Mitsui Global Investment
  192. Montisera
  193. MS Ventures
  194. National Institute of Mental Health
  195. National Institute of Neurological Disorders and Stroke
  196. National Institutes of Health
  197. National Science Foundation
  198. Netherlands Translational Research Center
  199. Neurocrine Biosciences
  200. NeuroDerm
  201. Neurodyn
  202. NeuroGeneration
  203. NeuroHealing Pharmaceuticals
  204. Neurolixis
  205. NeuroNascent
  206. NeurOp
  207. Neuropore Therapies
  208. New World Laboratories
  209. Newron Pharmaceuticals
  210. NewYork-Presbyterian Hospital  
  211. Nice & Green
  212. nLife Therapeutics
  213. NLS Pharma
  214. Nordic Life Sciences
  215. Novartis
  216. Novo Holdings
  217. Nutriband
  218. NYU Langone Health
  219. Oncodesign 
  220. OPKO Health
  221. Oregon Health and Science University
  222. Orion
  223. Osmotica Pharmaceutical
  224. Otsuka Pharmaceuticals
  225. Oulu Deaconess Institute  
  226. Oxalys Pharmaceuticals
  227. Oxford BioMedica
  228. Partner Fund Management
  229. Partners Innovation Fund
  230. Peptron
  231. Perceptive Advisors
  232. Pfizer Venture Investment
  233. Pharma Two B
  234. Pharnext
  235. Plex Pharmaceuticals
  236. Plymouth University Peninsula Schools of Medicine and Dentistry
  237. Prana Biotechnology
  238. Prexton Therapeutics
  239. Priavoid
  240. Primary Peptides
  241. ProbeX
  242. Proclara Biosciences
  243. ProMIS Neurosciences
  244. Promius Pharma
  245. Prothena Biosciences
  246. QR Pharma
  247. Quintiles Transnational
  248. RaQualia Pharma
  249. Regis Duffy BioScience Fund
  250. reMYND
  251. Retrotope
  252. Roche
  253. Rush University Medical Center
  254. SAGE Therapeutics
  255. SalubRx Therapeutics
  256. Saniona
  257. Sanofi
  258. Santo Venture Capital
  259. Scottish Enterprise
  260. Seeds Capital
  261. Seoul National University Hospital
  262. Serina Therapeutics
  263. Seroba Life Science
  264. S eventure Partners
  265. Shire
  266. SK Biopharmaceuticals
  267. Sodiv
  268. Sofinnova Partners
  269. Solstice Neurosciences
  270. Sphera Global Healthcare Fund
  271. SR One
  272. STADA Arzneimittel
  273. StrataGent Life Sciences
  274. Sumitomo Dainippon Pharma
  275. Sun Pharma Advanced Research Company
  276. Sunovion
  277. Sunstone Capital
  278. Swedish Research Council
  279. Syntonix Pharmaceuticals
  280. Takeda Pharmaceutical
  281. TauRx Therapeutics
  282. TechnoPhage
  283. Teikoku Pharma USA
  284. Tekes
  285. Teva Pharmaceutical 
  286. The Michael J
  287. Theranostics Health 
  288. Theravance Biopharma
  289. Thiel Foundation
  290. Third Rock Ventures
  291. Titan Pharmaceuticals
  292. Toulouse University Hospital 
  293. Transition Therapeutics
  294. Tri-CAP
  295. Trigen Holdings 
  296. Tsinghua University
  297. UCB Pharma
  298. United Neuroscience
  299. University Hospital of Lille
  300. University of Aberdeen
  301. University of California
  302. University of Cologne
  303. University of Florida
  304. University of Lisbon
  305. University of Miami
  306. University of Nebraska
  307. University of Puerto Rico
  308. University of South Florida
  309. University of Tübingen
  310. University of Western Ontario
  311. University of Zurich
  312. Uppsala University
  313. US WorldMeds
  314. V ClinBio
  315. venBio
  316. Versant Ventures
  317. Vertical   Pharmaceuticals
  318. Victor Company of Japan
  319. Vinnova
  320. Vivo Capital
  321. Vivreon Biosciences
  322. Voyager Therapeutics
  323. Wellington Management 
  324. Woodford Patient Capital Trust
  325. XenoPort
  326. Xoc Pharmaceuticals
  327. Yorkville Advisors
  328. Ysios Capital
  329. Zambon
     

PRICING DETAILS

USD 2,349

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.